| Table 3: | ||||||
|
Comparison
of Newer Atypical Antipsychotics
|
||||||
|
Atypical
Antipsychotic
|
Initial
Dose(mg)
|
Standard
Dose(mg/day)
|
Dosing
Frequency |
Max
Dose |
Advantages
|
Disadvantages
|
|
Clozapine
|
25-50
|
300-600
|
bid
|
900
|
Effective
in refractory schizophrenia
Lowest risk of extrapyramidal symptoms (EPS) |
Agranulocytosis
No liquid form No injectable form Weight gain, seizures |
|
Olanzapine
|
5-10
|
15-20
|
qd
to bid
|
20
|
Well
tolerated
Approved for acute mania |
Weight
gain
No liquid form No injectable form |
|
Quetiapine
|
25-50
|
400-600
|
bid
|
800
|
Well
tolerated
Lowest EPS risk |
Slow
titration
Sedation No liquid form No injectable form |
|
Risperidone
|
1-2
|
4-8
|
qd
to bid
|
16
|
Well
tolerated
Well-defined dose range |
Dose-dependent
EPS
No injectable form |
|
Ziprasidone
|
40-80
|
80-160
|
bid
|
160
|
Well
tolerated
No weight gain Injectable form |
qT
prolongation
Taken with food Nausea, insomnia No liquid form |
Return to Schizophrenia Chapter